New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio has managed to draw in an impressive $372 million series D as the AI-focused biotech seeks to expand its ... Both gusacitinib and ASN008 were bought from Asana BioSciences in ...

Formation Bio has raised $372 million for its AI-powered tech to speed up drug development processes. OpenAI CEO Sam Altman is an investor.

Formation Bio has secured $372m in a Series D financing round to bolster its drug pipeline and expedite the expansion of its AI-driven drug development platform. Spearheaded by venture capital ...

Formation Bio, a tech-driven and AI-native pharma company, announced today that it has raised $372MM of Series D financing. The financing was led by a16z with significant participation from Sanofi.

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of ...

AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi .

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.